Managing Radiotherapy-Induced Oral Mucositis with Photobiomodulation
For patients undergoing radiotherapy for head and neck cancers, oral mucositis (OM) is a frequent and debilitating side effect. This condition manifests as painful, ulcerative lesions in the oral mucosa, which can severely impair a patient’s ability to eat, speak, and maintain basic oral hygiene. To combat this, photobiomodulation (PBM) has emerged as a promising, non-invasive supportive therapy to reduce the severity of these lesions and improve quality of life.
What is Oral Mucositis?
Oral mucositis is characterized by inflammation, erythema, and ulceration of the mucosal lining within the oral cavity. It is primarily triggered by the cytotoxic effects of ionizing radiation and chemotherapy on rapidly dividing epithelial cells. The progression of OM follows a pathobiological cascade that begins with initiating tissue injury and continues through the signaling and amplification of pro-inflammatory cytokines.
How Photobiomodulation Works
Photobiomodulation therapy (PBMT) uses low-intensity light sources—typically lasers or LEDs—to promote healing and reduce pain. By utilizing specific wavelengths, usually between 630 and 980 nm, PBMT enhances cellular metabolism and promotes mucosal healing while reducing inflammation. Common clinical protocols involve energy densities of 2–6 J/cm² and application durations ranging from 10 to 125 seconds per point.
The Impact of PBM on Oxidative Stress and Inflammation
Recent research published in Nature evaluated the effects of intraoral (IOPBM) and extraoral (EOPBM) photobiomodulation on patients with head and neck squamous cell carcinoma (HNSCC). The study focused on salivary biomarkers to understand how PBM modulates the body’s response to radiotherapy.
Enhancing Antioxidant Defenses
Radiotherapy often induces oxidative stress, which contributes to tissue damage. The study found that PBM-treated patients exhibited significantly better antioxidant profiles compared to control groups:
- Superoxide Dismutase (SOD): SOD activity remained consistently elevated throughout radiotherapy in patients receiving PBM.
- Glutathione (GSH): Levels of GSH, a critical antioxidant, increased at the mid-point of radiotherapy.
Modulating Inflammatory Responses
Inflammation is a primary driver of the pain and ulceration associated with OM. PBM helps regulate this response by altering the levels of inflammatory cytokines in the saliva. Specifically, levels of interleukin-6 (IL-6) and interleukin-10 (IL-10) decreased from the start to the end of radiotherapy in PBM-treated patients compared to the control group.
Key Biomarker Findings
The research also tracked myeloperoxidase (MPO) and malondialdehyde (MDA). MPO activity was significantly higher across all radiotherapy time points and OM severity grades compared to the control group. While MDA levels showed a transient increase at mid-radiotherapy—particularly in the intraoral PBM group—this increase was not associated with the actual severity of the oral mucositis.
Clinical Outcomes and Application
In the clinical study, PBM was applied five times weekly from the initiation of radiotherapy until the oral mucositis healed. While all patients in the study developed some form of OM, fewer than 40% experienced severe cases. Evidence indicates that PBMT significantly reduces both the severity and duration of OM, which minimizes treatment-related morbidity and improves patient-reported outcomes.
- PBM reduces OM severity: Low-intensity light therapy limits the duration and intensity of oral ulcers.
- Boosts Antioxidants: PBM increases SOD and GSH levels, helping the body fight radiotherapy-induced oxidative stress.
- Controls Inflammation: Treatment leads to a decrease in inflammatory cytokines like IL-6 and IL-10.
- Non-Invasive: PBM provides a supportive, non-invasive way to manage toxicity without interfering with cancer treatment.
Frequently Asked Questions
Is PBM used to treat cancer?
No. In the context of oral mucositis, PBM is used as a supportive therapy to manage the side effects of radiotherapy and is not used as a treatment for the cancer itself.
What is the difference between intraoral and extraoral PBM?
Intraoral PBM (IOPBM) involves applying the light source directly inside the mouth, while extraoral PBM (EOPBM) applies the light from outside the oral cavity. Both methods have been shown to modulate inflammatory responses and enhance antioxidant defenses.
How often is PBM applied during radiotherapy?
Based on clinical evidence, PBM is often applied five times weekly, starting from the beginning of radiotherapy and continuing until the oral mucositis has healed.
Conclusion
Photobiomodulation represents a significant advancement in supportive oncology care. By enhancing the body’s natural antioxidant defenses and suppressing pro-inflammatory cytokines, PBM reduces the physical burden of oral mucositis. As standardization of laser protocols continues, PBMT is poised to grow a routine component of care for patients undergoing head and neck radiotherapy, ensuring better recovery and a higher quality of life during treatment.